Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions
-
Published:2022-08-31
Issue:1
Volume:13
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Wang Shirley V.ORCID, Sreedhara Sushama Kattinakere, Schneeweiss Sebastian, Franklin Jessica M.ORCID, Gagne Joshua J., Huybrechts Krista F., Patorno Elisabetta, Jin Yinzhu, Lee Moa, Mahesri Mufaddal, Pawar Ajinkya, Barberio Julie, Bessette Lily G.ORCID, Chin Kristyn, Gautam Nileesa, Ortiz Adrian Santiago, Sears Ellen, Stefanini Kristina, Zakarian Mimi, Dejene Sara, Rogers James R., Brill Gregory, Landon Joan, Lii Joyce, Tsacogianis Theodore, Vine Seanna, Garry Elizabeth M.ORCID, Gibbs Liza R.ORCID, Gierada Monica, Isaman Danielle L., Payne EmmaORCID, Alwardt Sarah, Arlett Peter, Bartels Dorothee B., Bate AndrewORCID, Berlin Jesse, Bourke Alison, Bradbury Brian, Brown Jeffrey, Burnett Karen, Brennan Troyen, Chan K. Arnold, Choi Nam-Kyong, de Vries Frank, Eichler Hans-Georg, Filion Kristian B., Freeman Lisa, Hallas Jesper, Happe Laura, Hennessy Sean, Jónsson PállORCID, Ioannidis John, Jimenez Javier, Kahler Kristijan H., Laine Christine, Loder Elizabeth, Makady Amr, Martin David, Nguyen Michael, Nosek Brian, Platt Richard, Platt Robert W., Seeger John, Shrank William, Smeeth Liam, Sørensen Henrik ToftORCID, Tugwell Peter, Uyama Yoshiaki, Willke Richard, Winkelmayer Wolfgang, Zarin Deborah,
Abstract
AbstractStudies that generate real-world evidence on the effects of medical products through analysis of digital data collected in clinical practice provide key insights for regulators, payers, and other healthcare decision-makers. Ensuring reproducibility of such findings is fundamental to effective evidence-based decision-making. We reproduce results for 150 studies published in peer-reviewed journals using the same healthcare databases as original investigators and evaluate the completeness of reporting for 250. Original and reproduction effect sizes were positively correlated (Pearson’s correlation = 0.85), a strong relationship with some room for improvement. The median and interquartile range for the relative magnitude of effect (e.g., hazard ratiooriginal/hazard ratioreproduction) is 1.0 [0.9, 1.1], range [0.3, 2.1]. While the majority of results are closely reproduced, a subset are not. The latter can be explained by incomplete reporting and updated data. Greater methodological transparency aligned with new guidance may further improve reproducibility and validity assessment, thus facilitating evidence-based decision-making. Study registration number: EUPAS19636.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference57 articles.
1. Eichler, H. G. et al. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97, 234–246 (2015). 2. Ball, R., Robb, M., Anderson, S. A. & Dal Pan, G. The FDA’s sentinel initiative—A comprehensive approach to medical product surveillance. Clin. Pharmacol. Ther. 99, 265–268 (2015). 3. Sun, X., Tan, J., Tang, L., Guo, J. J. & Li, X. Real world evidence: experience and lessons from China. BMJ 360, j5262 (2018). 4. Makady, A. et al. Policies for use of real-world data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. Value Health.: J. Int. Soc. Pharmacoeconomics Outcomes Res. 20, 520–532 (2017). 5. Schneeweiss S., Suissa S., in Pharmacoepidemiology, Strom B., Hennessey S., Kimmel S., Eds. (John Wiley & Sons, Chichester, 2012), pp. 868-891.
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|